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Protein folding quality control in cells requires the activity of a class of proteins known as 
molecular chaperones. Heat shock protein-90 (Hsp90), a multidomain ATP driven molecular 
machine, is a prime representative of this family of proteins. Interactions between Hsp90, its co-
chaperones, and client proteins have been shown to be important in facilitating the correct folding 
and activation of clients. Hsp90 levels and functions are elevated in tumor cells. Here, we 
computationally predict the regions on the native structures of clients c-Abl, c-Src, Cdk4, B-Raf and 
Glucocorticoid Receptor, that have the highest probability of undergoing local unfolding, despite 
being ordered in their native structures. Such regions represent potential ideal interaction points 
with the Hsp90-system. We synthesize mimics spanning these regions and confirm their 
interaction with partners of the Hsp90 complex (Hsp90, Cdc37 and Aha1) by Nuclear Magnetic 
Resonance (NMR). Designed mimics selectively disrupt the association of their respective clients 
with the Hsp90 machinery, leaving unrelated clients unperturbed and causing apoptosis in cancer 
cells. Overall, selective targeting of Hsp90 protein-protein interactions is achieved without causing 
indiscriminate degradation of all clients, setting the stage for the development of therapeutics 
based on specific chaperone:client perturbation. 
 
 
The Hsp90 family of molecular chaperones plays key roles in cell proteostasis by balancing the 
folding, activation, and turnover of a diverse set of client proteins, many of which fundamental for 
cancer development. Proteins of the Hsp90 family (Hsp90 in the cytosol, Grp94 in the ER and 
Trap1 in mitochondria) are homodimers with each individual chain consisting of three globular 
domains, the N-terminal (NTD), Middle and C-terminal (CTD). X-ray, SAXS and kinetic 
measurements have led to a mechanistic model in which global conformational modulations are 
triggered by ATP: ATP binding at the N-terminal domain [1] shifts the chaperone to a partially 
closed, and then into an asymmetric closed conformation that is significantly strained at the 
Middle:CTD interface, the region involved in client binding[2]. Upon ATP hydrolysis, strain is 
relieved through rearrangement of the client binding-site residues, driving structural changes in 
the client [3]. In this framework, ATP hydrolysis is coupled to client remodeling.  For these reasons, 
pharmacological intervention on Hsp90-controlled processed has largely relied on the use of ATP-
competitive inhibitors [4]. Hsp90 inhibition by ATP competitive inhibitors determines, however, 
the indiscriminate depletion of all Hsp90 clients, ultimately causing the upregulation of the heat 
shock response which ends up protecting cancer cells from apoptosis and causing toxicity [4g, 5].  
The formation of client:Hsp90 complexes is a critical step in the regulation of specific client 
activities. Specificity in the selection of clients that lack sequence and structural homology [6] is 
acquired through recruiter cochaperones that provide the essential recognition/discrimination 
elements [7]. In this framework, Hsp90, its cochaperones and the clients engage in 
multicomponent assemblies, stabilized by dynamic protein-protein interactions (PPIs). Co-
chaperones such as Cdc37 control the entry of kinases and other clients into the chaperone cycle 
[8],[9],[10], while other co-chaperones, such as Aha1, provide additional layers of regulation by 
modulating the rates of ATP hydrolysis[11]. No specific structural elements or surface 
characteristics have been proposed as Hsp90-binding determinants [12],[13],[14]. Critical to Hsp90 
mechanisms is that the interactions involved are conformationally heterogeneous, short-lived and 
relatively weak, with different clients interacting in distinct ways [15],[16],[17],[18].  
These observations unveil a new opportunity for the design of client-selective chemical tools 
based on the idea that perturbing the (weak) interactions with (any of) the members of the 
chaperone assembly can impair a client’s folding. The lack of consensus binding motifs suggests 
the possibility to target unique interaction surfaces in order to specifically disrupt key 
client:chaperone or client:co-chaperone interactions. 
 Here, we predicted interaction interfaces of different clients, based only on the structure 
of the isolated client, as the rational basis for the design of selective peptide inhibitors of protein-
protein interactions in chaperone complexes. The design is based on a novel computational 
method we recently developed for the prediction of locally unstable substructures in proteins. 
Here, the unstable substructures do not coincide with intrinsically disordered regions or coils 
(which may indeed be thermodynamically stable); rather they represent protein regions that, 
despite being ordered in the native state, have a high probability/tendency to undergo local 
unfolding and support conformational transitions leading to conformational heterogeneity [19]. 
These particular substructures thus represent potential ideal points of interaction with the Hsp90 
machinery [2d, 20]. This knowledge is translated into the development of peptides spanning the 
predicted interaction sites with the aim to engage different constituents of the Hsp90 complex 
(Hsp90, Cdc37, Aha1). The ability of the designed molecules to bind to their chaperone complex 
members was confirmed by NMR. The peptides were cell permeable and selectively interfered 
with the association of their respective clients with the Hsp90 chaperone machinery, ultimately 
causing apoptosis in cancer cells. To the best of our knowledge, our work represents the first 
example in which ab initio, physics-based characterization of protein stability is leveraged for the 
selective chemical targeting of chaperone:client interactions in multicomponent complexes. This is 
achieved without significant indiscriminate inhibition or degradation of all clients, setting the stage 
for the definition of the pharmacophoric requirements for the development of PPI targeting 
molecules with therapeutic potential. We suggest that this approach can be extended to block the 
folding of otherwise undruggable proteins, providing a novel opportunity to block the pathologic 
activities of biomolecules for which no drug has been developed. 
Computational design and NMR-characterization. The Hsp90 system acts on clients late in their 
folding pathway and associates with substrates in which large parts of the domains are already 
folded in their native conformation. We therefore hypothesize that the chaperone system targets 
client substructures with minimal structural stability in the native state. From the physico-
chemical point of view, locally-unstable substructures are characterized by distinct energetic 
properties as they are not involved in major intramolecular stabilizing interactions with other 
regions of the protein. Minimal intramolecular coupling, in turn, favors local instability and 
structural variations, distinctive properties of local unfolding.  
To predict the location of minimally coupled, locally unstable substructures, we used the MLCE 
method [19b, 21] [see SI Methods]. We first tested our approach on the Hsp90 client Abelson 
leukemia (c-Abl) kinase protein. Two consensus sequences, labeled respectively A01 and A02 
(Figure 1, Table 1), were designed as potential interaction epitopes by applying MLCE to MD 
simulations of c-Abl. A01 represents a conformational epitope localized at the N-lobe at the 
border with the C-lobe, spanning parts of the Gly-rich loop, β1, β2 and β3 strands and the αC helix 
(Figure 1). To achieve optimal spanning of predicted interaction regions, we linked the different 
constituent subparts by the addition of a number of glycine residues approximating the average 
distance between the respective terminals calculated from MD simulations (see Table 1). The 
second epitope, A02, is linear, located at the C-lobe, and spans the αG-helix preceded by the 
flexible αF loop. An 19F-modified phenyl alanine was site-specifically introduced into A01 and A02 
to allow the characterization of the binding to members of the Hsp90 chaperone complexes 
(Hsp90, Cdc37, Aha1) by Fluorine Nuclear Magnetic Resonance (19F NMR) [22],[23] (see Table 
1).Human Serum Albumin (HSA) was used as a control for non-specific binding.  
  
   
 
Figure 1. The 3D structures and names of the proteins analyzed in the paper. The regions colored 
in red are the substructures predicted to undergo unfolding and to be points of interaction with 
the members of the Hsp90 chaperone machinery. 
  
First, we tested the peptides individually at 10 M in the presence and in absence of full length 
human Hsp90 by 19F R2 filter experiments. The 19F NMR signals of A01 and A02 decrease in the 
presence of Hsp90, indicating peptide-protein binding (Figure 2a, traces 1 and 2). Interestingly A01 
and A02 continue to bind to Hsp90 even when they are tested together, suggesting that they do 
not compete with each other and interact with different sites. Next, we ran 19F-NMR interaction 
experiments testing 10 M of each cAbl peptide against Aha1 and Cdc37. A01 showed the ability 
to bind Cdc37, while showing no binding to Aha1. We also checked the binding of 40 M A01 and 
40 M A02 with 10 M HSA: importantly, neither A01 nor A02 showed interaction with HSA (see 
Supporting Information Figure SI1).  
To investigate the generality of our strategy, we next designed mimics of the chaperone-binding 
regions of oncogenic kinase B-Raf and extended MLCE-predictions to glucocorticoid receptor (GR), 
a protein with structure, substrate and functions that are completely unrelated to kinases. In B-
Raf, two conformational epitopes were predicted, labeled B-Raf-01 and B-Raf-02 (Figure 1, Table 
1), located in the N-lobe of the kinase at the border with the C-lobe. Interestingly, while the 19F 
NMR signals of peptides B-Raf-01 and B-Raf-02 (Figure 2a, traces 3 and 4) do not show any 
difference in the presence of Hsp90, indicating no or very weak interaction, B-Raf-02 binds to 
Cdc37 (Figure 2a, trace 4). Importantly, no interactions are detected with HSA (see Supporting 








Figure 2. (a) 19F NMR experiments showing the binding of Abl and Braf peptides to the proteins of 
the Hsp90 chaperone system. The subpanels indicate the interactions of (1) Peptide A01; (2) A02; 
(3) B-Raf01; (4) B-Raf02; (5) all peptides are mixed together and added to the solution containing 
the protein. The NMR signals show no variation compared to the situation with the single 
peptides, indicating that there is no competition among the different sequences. (b) 19F NMR 
experiments showing the binding of GR peptides to the proteins of the Hsp90 chaperone system. 
(1) Peptide GR-01; (2) GR-02; (3) both peptides are mixed together and added to the solution 
containing the protein. The NMR signals show that GR-02 binds to all the protein, but the binding 
effect is higher on CDC37. No significant differences are observed in the binding of GR-02 in 
presence of GR-01. 
 
 
In GR[24], two substructures were predicted (Figure 1, Table1). Interestingly, they correspond to 
the region that Kirschke et al. [25] previously observed to engage the Hsp90 complex. 19F-NMR 
confirmed binding of synthetic mimics of GR unfolding regions to the members of the chaperone 
complex. GR-02, in particular, binds to all the tested proteins, with the highest effect on Cdc37 
(Figure 2, trace 2). 
Because NMR data supported the viability of our prediction and design approach, we extended 
our analysis to oncogenic kinases Cdk4 and c-Src for further testing in cancer cells. In Cdk4, the 
unfolding regions localize mainly in the N-lobe, corresponding to the region undergoing unfolding 
in the Agard cryoEM structure [20a]. In c-Src, an additional epitope traces the G4 helix in the C-
lobe (see Figure 1, Table 1). 
Effect of c-Abl peptides on Hsp90 chaperone complex in human cells. To demonstrate the impact 
of the peptides based on c-Abl–Hsp90 interactions, we treated HEK293 cells with A01 and A02. We 
demonstrated a decrease of c-Abl protein levels and dissociation of c-Abl from Hsp90, consistent 
with interference of Hsp90 chaperoning by A01 and/or A02 (Figure 3a). Importantly, neither the 
related kinase c-Src nor the client kinases Cdk4 or Akt showed a defect in stability or activity, 
indicating the specificity of the A01 and A02 designed peptide epitopes for c-Abl (Figure 3a).  
 
 
Figure 3. (a) HEK293 cells were treated with 10µM A01 or A02 with and without TAT. After 36 
hours, lysate was prepared from the cells followed by immunoprecipitation of endogenous Hsp90. 
Inputs and co-immunoprecipitated proteins were evaluated by immunoblotting. GAPDH was used 
as a loading control. NT = no treatment. (b) Hsp90⍺-FLAG or Hsp90β–FLAG were overexpressed in 
HEK293 cells. Hsp90 binding to biotinylated A01 and A02 was examined by immunoblotting. 
 
 
We have previously published that c-Abl phosphorylates Aha1-Y223 and promotes its binding to 
Hsp90 [26]. A01 and A02 treatment decreased Aha1-Hsp90 complex formation, demonstrating 
that the peptide-mediated dissociation of c-Abl and Hsp90 elicits a functional consequence (Figure 
3a). We next tested whether A01 and A02 preferred a particular isoform of Hsp90, the 
constitutively expressed Hsp90β or the stress-inducible Hsp90α. Streptavidin-pulldown of the 
biotinylated peptides shows A01 binds with higher affinity to both isoforms of Hsp90 but neither 
peptide demonstrates isoform specificity (Figure 3b). Taken together we have demonstrated that 
our c-Abl–mimic peptides can disrupt the specific interaction of this client kinase with Hsp90 in 
cells. 
Physiological impact of Hsp90 client-based peptides. Our data with the c-Abl-based inhibitors 
prompted us to examine the impact of additional peptides spanning the predicted interaction 
regions of other clients (B-Raf, Cdk4, c-Src and GR) on their respective client:chaperone 
interactions. Treating HEK293 cells with increasing concentrations of these peptides led to 
dissociation of the clients from Hsp90 (Figure 4a-d). We confirmed that these peptides labeled 
with fluorescein can readily enter HEK293 cells (Figure 4e). We further examined the effect of 
these peptides in cancer cells. We treated the clear cell renal cell carcinoma cell line 786-O with B-
Raf, Cdk4, and c-Src-based inhibitors. All the mimicking peptides, except c-Src02, and induced 
apoptosis, as revealed by the induction of the apoptotic marker cleaved caspase-3 (Figure 4f). 
Finally, we have also treated the 786-O cells with GR-based inhibitors (GR-01 and GR-02) and 
showed GR dissociation from Hsp90 (Figure 4g). Taken together, these data indicate that the 
designed peptides have the ability to enter cells and dissociate client proteins from Hsp90. They 
also demonstrate biological activity as they induce apoptosis in a cancer cell line. 
 
Discussion and Conclusions. We have developed an integrated approach combining ab initio 
design, synthesis and cellular testing to advance the mechanistic investigation of protein stability. 
We leveraged this strategy to the design molecules that selectively interfere with Hsp90-mediated 
protein folding. Our data show that predicted locally unstable regions from the native structures 
of clients can define the preferential points of interaction with members of the Hsp90 system, and 
can be mimicked by synthetic peptide agents spanning such regions. These rationally designed 
chemical tools induce selective dissociation and/or degradation of cognate clients in cells.  
Here, we introduce a novel concept of selective targeted protein depletion based on the 
interference with the protein-protein interactions (PPI) that underpin Hsp90-mediated folding 
processes. Binding of the synthetic peptide agents to Hsp90 and/or its cochaperones Cdc37 and 
Aha1 interferes with the formation of the complexes that control protein conformational 
maturation [27],[7],[28],[18]. It is worth noting that the affinities between Hsp90, cochaperones 
and clients are weak and only when all the components are correctly assembled do the complexes 
become functional. The client-mimicking PPI inhibitors can specifically target Hsp90 and/or 
Cdc37/Aha1, disrupt the binding of the clients to the chaperone complex and significantly reduce 
their cellular levels, perhaps due to their degradation. 
At the atomic level, the EM structure from the Agard lab shows the N- and C- lobes of Cdk4 in 
complex with Hsp90-Cdc37 are completely separated, with the hinge region including the αC helix 
largely unfolded [20a]. Importantly, the location of the hinge largely overlaps with the 
substructures at the border between the N- and C-lobes that we predict to be most prone to 
unfolding (Figure 5). Our model is thus supported by and further corroborates EM-based 
observations. If the Hsp90 dependency of a kinase is linked to the tendency of the N-lobe and C-
lobe to separate in an open state, the interaction surfaces are not random, but should correspond 
to energetically uncoupled regions that support the conformational reorganization leading to the 
separation of the two domains. Furthermore, existing data on GR point to regions that are 
reshaped during the formation of chaperone complexes and that significantly overlap with our 
designs [25].  
 
 
Figure 4. (a) Endogenous Hsp90 was immunopreciptated from HEK293 cells treated with the 
indicated amounts of B-Raf peptides. Hsp90 binding to B-raf was evaluated by immunoblotting. (b) 
Binding of Hsp90 and Cdk4 was evaluated by immunoblotting after treatment with the indicated 
concentrations of Cdk4-01 and Cdk4-02 and immunoprecipitation of endogenous Hsp90. (c) 
Binding of Hsp90 and c-Src was evaluated by immunoblotting after treatment with the indicated 
concentrations of c-Src-01 and c-Src-02 and immunoprecipitation of endogenous Hsp90. (d) 
HEK293 cells were treated with the indicated amounts of GR-01 or GR-02 then examined for total 
GR protein by immunoblotting. (e) Representative microscopy images of drug uptake in HEK293 
cells treated with 10µM FAM- labeled peptides for 24h. Scale bar = 100µm. NT = non-treated (f) 
Apoptosis in cancer cells was evaluated by immunoblotting for the apoptotic marker cleaved 
caspase-3 in 786-O cells treated with the kinase peptide mimics. (g) Apoptosis in cancer cells was 
evaluated by immunoblotting for the apoptotic marker cleaved caspase-3 in 786-O cells treated 
















Figure 5. Structural superposition of the Cdk4 structure in complex with Hsp90 and Cdc37 in the 
original Cryo-EM structure (5FWK) with the structure of the Abl kinase (yellow). For clarity only 
Hsp90 (gray surface) and Cdk4 (blue) are displayed. The Cdk4 is superimposed to Abl (yellow) by 
overlapping the C-lobe. The red van der Waals spheres represent the predicted Hsp90 binding 
region, which appears to optimally trace the surface of Hsp90 and overlap with the unfolding part 
of Cdk4. 
 
To our knowledge, our work represents the first example of selective chemical targeting of Hsp90 
PPIs without significant inhibition or degradation of all chaperone clients. The notion that selective 
clearance of oncogenic clients can be achieved through perturbation of Hsp90 PPIs has 
implications for both mechanistic studies and for future therapeutic applications. Mechanistically, 
selective degradation of specific oncoproteins can be used as a complement to molecular biology 
to investigate their relevance in signaling pathways. In summary, amino-acid stretches with 
minimal intra-client coupling can be the drivers of selective degradation of specific Hsp90 client 
proteins. Synthetic mimics of these regions could possibly have advantages over ATP-competitive 
Hsp90 inhibitors.  The latter compounds unselectively target the entire spectrum of Hsp90 client 
proteins, causing their destabilization. This lack of selectivity is frequently associated to toxicity, 
which limit the clinical application of those agents. In contrast, the perturbation of the Hsp90 PPIs 
with specific clients by our molecules enables a controlled modulation of chaperone networks. 
Finally, we suggest that the discovery of molecular entities that block chaperone mediated folding 




Table 1. Sequences of the mimics of chaperone binding regions.  
Protein Mimic Name Sequence[a,b] 
c-Abl A01 (248)LGGGQFGEVY(265)-GG-(267)VAVKTL(274)-GGG-(282)EFLDEAAVMK(291) 
 A02 FGG(438)SPYPGIDLSQVYELLEK(454) 
B-Raf B-Raf-01 GYSTKPQLA(79)GGG(39)NVTAPTPQ(46)G-(163)F-QHSGS(158) 
 B-Raf-02 (22)FGTVYKGKW(29)GGG(71)GF-STKPQLA(79)GGG(39)NVTAPTPQ(46) 
Cdk4 Cdk4-01 (83)CATSRTDRE(91)G(45)PNGGGGGGGLPIST(58)GG(172)FQMALTPVV(180)   
 Cdk4-02 (13)PVAEIGVGAYG(23)GG(43)RVP(45)GG(172)FQMALTPVV(180) 
cSrc cSrc-01
 (21)LGQGCFG(27)G(46)KPGTMSP(52)GG(79)EEP(81)GG(12)RESL(15)G(34)WNGTT(38) 
 cSrc-02 (100)GEMGK(104)GG(206)KGRVPYPGMVNREVLDQVERGFRM(229) 
GR GR-01 (635)TLPC(638)GG(556)TWRIMT(561)G(747)IEFPEMLA(754) 
 GR-02 (545)YAGYDSSVPDSTWRIMTTLNM(565)GG(749)FPEMLA(754) 
[a] The numbering in square brackets reports the numbering in the original pdb file, reported in 
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